NASDAQ:ONCR

Oncorus (ONCR) Stock Forecast, Price & News

$0.18

-0.02 (-10.02%)

(As of 03:57 PM ET)

Compare

Today's Range: $0.18
▼
$0.19
50-Day Range: $0.19
▼
$0.36
52-Week Range: $0.17
▼
$1.90

Volume: 755,961 shs
Average Volume: 337,764 shs
Market Capitalization: $4.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

Oncorus MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 1,833.7% Upside
$3.50 Price Target
Short Interest: Healthy
0.95% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Oncorus has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.50, Oncorus has a forecasted upside of 1,833.7% from its current price of $0.18.
Amount of Analyst Coverage
Oncorus has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.95% of the float of Oncorus has been sold short.
Short Interest Ratio / Days to Cover
Oncorus has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Oncorus has recently decreased by 3.35%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Oncorus does not currently pay a dividend.
Dividend Growth
Oncorus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ONCR.

2.7

News and Social Media Coverage

News Sentiment
Oncorus has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oncorus insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.90% of the stock of Oncorus is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.69% of the stock of Oncorus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Oncorus is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oncorus is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oncorus has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Oncorus (NASDAQ:ONCR) Stock

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive ONCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncorus and its competitors with MarketBeat's FREE daily newsletter.

ONCR Stock News Headlines

May 23, 2023 | finanznachrichten.de

Oncorus, Inc.: Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

May 23, 2023 | americanbankingnews.com

Oncorus (NASDAQ:ONCR) Announces Quarterly Earnings Results, Misses Estimates By $0.48 EPS

June 1, 2023 | Edge On The Street (Ad)

AI is Unstoppable. Now Is The Time!

AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.

May 22, 2023 | msn.com

Recap: Oncorus Q1 Earnings

May 22, 2023 | finance.yahoo.com

Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates

April 16, 2023 | americanbankingnews.com

Contrasting Oncorus (NASDAQ:ONCR) and BridgeBio Pharma (NASDAQ:BBIO)

March 29, 2023 | americanbankingnews.com

HC Wainwright Brokers Raise Earnings Estimates for Oncorus, Inc. (NASDAQ:ONCR)

March 24, 2023 | finanznachrichten.de

Oncorus, Inc.: Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

June 1, 2023 | Edge On The Street (Ad)

AI is Unstoppable. Now Is The Time!

AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.

March 24, 2023 | finance.yahoo.com

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 15, 2023 | bizjournals.com

For some biotechs moving on from SVB, not all traditional banks are an option

March 11, 2023 | markets.businessinsider.com

Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank

January 4, 2023 | finance.yahoo.com

Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

November 30, 2022 | marketwatch.com

Oncorus Shares Plumb New Depths on Job Cuts, Portfolio Reshaping >ONCR

November 30, 2022 | finance.yahoo.com

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

November 23, 2022 | finance.yahoo.com

Oncorus to Participate in Upcoming Investor Conferences

November 18, 2022 | finance.yahoo.com

Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

November 7, 2022 | finance.yahoo.com

Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade

November 2, 2022 | msn.com

Recap: Oncorus Q3 Earnings

October 8, 2022 | fool.com

Oncorus, Inc. (NASDAQ: ONCR)

October 7, 2022 | finance.yahoo.com

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

October 5, 2022 | theglobeandmail.com

Oncorus: Top 10 Undervalued Healthcare Stocks on NAS (ONCR)

September 26, 2022 | benzinga.com

Oncorus to Present at Chardan's 6th Annual Genetic Medicines Conference

September 26, 2022 | finance.yahoo.com

Oncorus to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 6, 2022 | finance.yahoo.com

Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 16, 2022 | finance.yahoo.com

Oncorus, Inc. (NASDAQ:ONCR) insiders recover some losses but still US$100k away from matching original investment

August 5, 2022 | reuters.com

ONCR.O - Oncorus Inc | Stock Price & Latest News | Reuters

See More Headlines

ONCR Price History

30 days | 90 days | 365 days | Advanced Chart

ONCR Company Calendar

Last Earnings: 5/22/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ONCR
CUSIP: N/A
CIK: 1671818
Web: www.oncorus.com
Phone: 339-240-3330
Fax: N/A
Employees: 82
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.50
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +1,833.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-77,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -134.31%
Return on Assets: -60.14%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.50
Quick Ratio: 1.50

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.19 per share
Price / Book: 0.15

Miscellaneous

Outstanding Shares: 26,090,000
Free Float: 21,946,000
Market Cap: $4.72 million
Optionable: Not Optionable
Beta: 2.82

Key Executives

Dr. Mitchell H. Finer Ph.D. (Age 63)
Non-Exec. Chairman
Comp: $127.75k

Dr. Theodore T. Ashburn M.D. (Age 55)
Ph.D., Pres, CEO & Director
Comp: $760.51k

Mr. Stephen W. Harbin (Age 63)
COO & Chief of Staff
Comp: $403.54k

Mr. Richard J. Wanstall M.B.A. (Age 53)
CFO, Chief Accounting Officer & Treasurer

Brian J. Shea
Director of Legal Counsel & Corp. Sec.

Dr. John Mayer Goldberg M.D. (Age 48)
Chief Medical Officer

Chris German
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ONCR Stock - Frequently Asked Questions

Should I buy or sell Oncorus stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oncorus in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ONCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCR, but not buy additional shares or sell existing shares.
View ONCR analyst ratings or view top-rated stocks.
What is Oncorus' stock price forecast for 2023?: 3 brokerages have issued 12-month price objectives for Oncorus' stock. Their ONCR share price forecasts range from $2.00 to $5.00. On average, they expect the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 1,833.7% from the stock's current price.
View analysts price targets for ONCR or view top-rated stocks among Wall Street analysts.
How have ONCR shares performed in 2023?: Oncorus' stock was trading at $0.2533 at the beginning of 2023. Since then, ONCR shares have decreased by 28.5% and is now trading at $0.1810.
View the best growth stocks for 2023 here.
When is Oncorus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ONCR earnings forecast.
How were Oncorus' earnings last quarter?: Oncorus, Inc. (NASDAQ:ONCR) posted its quarterly earnings results on Monday, May, 22nd. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.48.
What other stocks do shareholders of Oncorus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Oncorus investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV), Atlas Air Worldwide (AAWW).

When did Oncorus IPO?: (ONCR) raised $87 million in an initial public offering on Friday, October 2nd 2020. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Jefferies, Evercore ISI and Piper Sandler served as the underwriters for the IPO.
What is Oncorus' stock symbol?: Oncorus trades on the NASDAQ under the ticker symbol "ONCR."
Who are Oncorus' major shareholders?: Oncorus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.55%) and SG Americas Securities LLC (0.48%). Insiders that own company stock include Christophe Queva, Ernest C Garcia II, James E Flynn, Luke Evnin, Rick Wanstall, Stephen Harbin and Sunstates Fund LP Mpm.
View institutional ownership trends.
How do I buy shares of Oncorus?: Shares of ONCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Oncorus' stock price today?: One share of ONCR stock can currently be purchased for approximately $0.18.
How much money does Oncorus make?: Oncorus (NASDAQ:ONCR) has a market capitalization of $4.72 million. The company earns $-77,420,000.00 in net income (profit) each year or ($3.49) on an earnings per share basis.
How can I contact Oncorus?: The official website for the company is www.oncorus.com. The company can be reached via phone at 339-240-3330 or via email at ir@oncorus.com.

This page (NASDAQ:ONCR) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial